Figure 6 Differences in glycaemic control with the study drug

Slides:

Advertisements

Similar presentations

Clinical Outcomes with Newer Antihyperglycemic Agents

Advertisements

Clinical Outcomes with Newer Antihyperglycemic Agents

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

LEADER trial: Primary Outcome

Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

Nat. Rev. Nephrol. doi: /nrneph

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Global Projections for Diabetes:

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Effect of dapagliflozin on HbA1c and body weight

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis Patricia M.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

T2DM and CV Outcomes Trials: A Deep Dive!

A Deep Dive Into CVOTs.

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Evidence for the incretin effect and

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The sensory and secretory function of the L cell

Figure 1 The burden of chronic kidney disease (CKD)

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Tackling CV Risk in T2DM.

Figure 1 Acute kidney injury and chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Figure 4 Effects of glucagon-like peptide 1 (GLP-1) and

Jun M, et al. Lancet 2010 Epub May 10

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Nat. Rev. Nephrol. doi: /nrneph

Antihyperglycemic Therapy

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Figure 1 Sites of action of glucose-lowering agents

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Preventive strategies for CSA-AKI

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Completed and ongoing CVOTs (6–14,39,44–58)

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Nat. Rev. Nephrol. doi: /nrneph

John J.V. McMurray et al. JCHF 2018;6:8-17

Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Presentation transcript:

Figure 6 Differences in glycaemic control with the study drug versus placebo in cardiovascular outcome studies assessing the safety of incretin-based therapies in patients with type 2 diabetes mellitus at high risk of cardiac events Figure 6 | Differences in glycaemic control with the study drug versus placebo in cardiovascular outcome studies assessing the safety of incretin-based therapies in patients with type 2 diabetes mellitus at high risk of cardiac events. Data obtained from Pfeffer et al. (ELIXA)212, Marso et al. (LEADER)65, Marso et al. (SUSTAIN-6)213, Scirica et al. (SAVOR-TIMI 53)215, White et al. (EXAMINE)216 and Green et al. (TECOS)217. EoT, end of treatment. Muskiet, M. H. A. et al. (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.123